Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.

Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.

Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.

A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.

A 14% ORR with IDRX-42 in fourth-line GIST looks better than the 9% previously seen with Qinlock.

After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.

But the groups have yet to see any responses with AU-007 and XTX202 respectively.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.